NGM313, a Novel Activator of β-Klotho/FGFR1c, Improves Insulin Resistance and Reduces Hepatic Fat in Obese, Nondiabetic Subjects

Publication Authors:

Depaoli, A; Phung, V; Bashir, M.R.; Morrow, L; Beysen, C; Yan, A; Ling, L; Baxter, B; Luskey, K.L.; Olefsky, J.M.

Poster presented at American Diabetes Association (ADA) 79th Scientific Sessions, San Francisco, CA. June 2019.

About

About this Poster:

NGM313 is a humanized monoclonal antibody activator of β-klotho/FGFR1c that has been shown to reduce HOMA-IR in obese subjects. This study compared the effects of a single dose of NGM313 vs. daily pioglitazone (PIO) on insulin sensitivity, liver fat content (LFC) and lipids in insulin resistant, obese subjects with increased liver fat.

VIEW
NGM313, a Novel Activator of β-Klotho/FGFR1c, Improves Insulin Resistance and Reduces Hepatic Fat in Obese, Nondiabetic Subjects thumbnail